Title: Ceftobiprole Approved in Canada for Treatment of Complicated Skin Infections
|
|
To print: Select File and then Print from your browser's menu Title: Ceftobiprole Approved in Canada for Treatment of Complicated Skin Infections |
|
"Ceftobiprole Approved in Canada for Treatment of Complicated Skin Infections" BASEL, Switzerland -- June 30, 2008 -- Health Canada has authorised the marketing of ceftobiprole medocaril for injection (ZEFTERA) for the treatment of complicated skin and soft tissue infections including diabetic foot infections. Ceftobiprole is the first approved broad-spectrum anti-methicillin-resistant [Staphylococcus aureus (MRSA) antibiotic belonging to the cephalosporin class. It is specially designed to bind the penicillin-resistant targets in many Gram-positive bacteria of the cocci-type, resulting in bactericidal activity towards MRSA and penicillin-resistant Streptococcus pneumoniae. Ceftobiprole as a single intravenous agent has demonstrated broad-spectrum activity against many other Gram-positive as well as Gram-negative bacteria, frequently associated with community and hospital-acquired infections. |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |